What is 2-AG (2-Arachidonoylglycerol)?

2-Arachidonoylglycerol (2-AG) is one of the two primary endocannabinoids produced naturally by the human body, alongside anandamide (AEA). This lipid-based neurotransmitter plays a crucial role in the endocannabinoid system (ECS), serving as the body's most abundant endogenous cannabinoid compound. 2-AG is synthesized on-demand from arachidonic acid and glycerol through enzymatic processes involving phospholipase C and diacylglycerol lipase. Unlike traditional neurotransmitters that are stored in vesicles, 2-AG is produced when needed and acts as a retrograde messenger, traveling backward across synapses to modulate neural activity. This endocannabinoid primarily binds to CB1 receptors in the brain and central nervous system, and CB2 receptors in immune tissues. Research indicates 2-AG concentrations in brain tissue are approximately 170 times higher than anandamide levels, making it the predominant endocannabinoid in neural tissues. 2-AG influences numerous physiological processes including pain perception, inflammation, appetite regulation, memory formation, and neuroprotection. Studies suggest it plays a significant role in synaptic plasticity and long-term depression, mechanisms essential for learning and memory consolidation. The compound is metabolized primarily by monoacylglycerol lipase (MAGL), which breaks down approximately 85% of brain 2-AG, and fatty acid amide hydrolase (FAAH). Understanding 2-AG metabolism has implications for cannabis research, as THC and other cannabinoids interact with the same receptor systems. Pharmaceutical companies are investigating 2-AG pathway modulation for therapeutic applications. MAGL inhibitors that increase 2-AG levels are being studied for treating neuroinflammation, epilepsy, and neurodegenerative diseases, representing a growing area of cannabinoid medicine research. *This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance regarding endocannabinoid system-related conditions.*